Skip to main content

Tweets

Do you think point of care #ultrasound should be mandatory in #rheumatologu #residency #training? @RheumNow @ACRheum #ACR23

Janet Pope ( View Tweet )

2 years 3 months ago
A good clinical trial should consist of not denying a standard of care comparator. Difficult to enrol in protocols requiring placebo in active disease. Maybe learn from #ped #rheum #RCTs where all get active #Rx then randomized to stop vs continue&trial designs. @RheumNow #ACR23 https://t.co/eQFEktsfBt

Janet Pope ( View Tweet )

2 years 3 months ago
A woman who knows how to integrate fashion into science. @ashira_md noted how TLR’s look like the Chanel brand @CHANEL #ACr23 @RheumNow @uptoTate @AWIRGROUP @gwenesta_melton #ScienceIsCool https://t.co/GQro9xR71W
TheDaoIndex @KDAO2011 ( View Tweet )
2 years 3 months ago
SLE Prosp Observational Cohort Study (SPOCS) reported realworld data on meds use in mod-to-severe SLE: ⬆️in GC dose in 1st 6mos then stable thru 36mos w/ stable antimalarials, mod⬆️in biologics, IS Key message? Addt'l tx needed to avoid high GC doses #ACR23 ABST0592 @RheumNow https://t.co/q5YGYKNG6S
sheila ( View Tweet )
2 years 3 months ago
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow and its faculty.

Dr. John Cush @RheumNow ( View Tweet )

2 years 3 months ago
CV events in women w/ ARDs pregnancies: -2.0% of 19,340 pregnant ARDs Adjusted relative risk: -4 fold in ARD -15 fold in primary APS -6 fold in SLE -SLE + APS 18 fold 25-30% occur in early post partum! Need for continued vigilance after delivery @RheumNow #ACR23 ABST0722 https://t.co/hLeN61WBnB
Aurelie Najm ( View Tweet )
2 years 3 months ago
CVE’s higher in pregnant pts with SLE + APS, primary APS and Lupus nephritis especially in the postpartum period. Rheums need to be involved with their patients’ care during pregnancy! Abstr#0722 #ACr23 @rheumnow https://t.co/P6sbJtd6xW
TheDaoIndex @KDAO2011 ( View Tweet )
2 years 3 months ago
Always great to see UCSD represent at #ACR23! Pregnant women with rheumatic diseases and antiphospholipid syndrome higher a HIGHER risk for acute cardiovascular events 30% of events occurred postpartum @RheumNow Abs#0722 https://t.co/CqZedfOlBC
Robert B Chao, MD ( View Tweet )
2 years 3 months ago
#ACR23 Real-world multicentre study showed steroid-sparing effect of Belimumab in #SLE. At 2 years, proportion of patients on =>10mg/d decreased from 52% to 3%. 18% and 13% achieved LLDAS and DORIS remission. Support its use esp. in those relying on glucocorticoids @RheumNow https://t.co/ad5XH3pmYc
Md Yuzaiful Md Yusof ( View Tweet )
2 years 3 months ago
Systemic anti-inflammatory treatments for PsO and PsA including methotrexate and biologics provided cardioprotective effects Potential cardiovascular benefits of IL-17i and IL-12/23i compared to TNFi @RheumNow #ACR23 Abs#0498 https://t.co/Np7PSNvFd6
Robert B Chao, MD ( View Tweet )
2 years 3 months ago
#ACRBest @RheumNow https://t.co/u6DiQbebTF

Aurelie Najm ( View Tweet )

2 years 3 months ago
Plenary 1 #ACR23 CVE in ARD/APS is a significant risk factor during pregnancies and the risk stays even after delivery for a significant amount of time. California based administrative data study! abst#722 @RheumNow https://t.co/HawhS4Gqko
Bella Mehta @bella_mehta ( View Tweet )
2 years 3 months ago
×